Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide

INTRODUCTION AND BACKGROUND: Second-line treatment of platinum-resistant relapsed/metastatic (R/M) head and neck cancer (HNC) is a currently unmet clinical need. Clinical trials showed improvement in overall survival and quality of life of R/M-HNC patients treated with anti-PD-1 regardless of the nu...

Descripción completa

Detalles Bibliográficos
Autores principales: Merlano, Marco C., Merlotti, Anna M., Licitra, Lisa, Denaro, Nerina, Fea, Elena, Galizia, Danilo, Di Maio, Massimo, Fruttero, Claudia, Curcio, Paola, Vecchio, Stefania, Russi, Elvio G., Corvò, Renzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107891/
https://www.ncbi.nlm.nih.gov/pubmed/30186977
http://dx.doi.org/10.1016/j.ctro.2018.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107891/
https://www.ncbi.nlm.nih.gov/pubmed/30186977
http://dx.doi.org/10.1016/j.ctro.2018.08.001

Ejemplares similares